Brandon M. Huffman

Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma

P. Wen, N. Bardeesy, B. Wolpin, 2022, npj Precision Oncology.

Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma

H. Ellis, B. Wolpin, A. Aguirre, 2022, Cancers.

Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma

J. Lacy, B. Wolpin, M. Morse, 2023, JAMA network open.

Diagnostic tool to identify and treat DNA repair deficient gastroesophageal adenocarcinomas

Z. Szallasi, I. Csabai, Harshabad Singh, 2022, bioRxiv.

Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma

G. Shapiro, A. D’Andrea, B. Wolpin, 2021, Clinical Cancer Research.

Replicative stress in gastroesophageal adenocarcinoma is associated with chromosomal instability and sensitivity to DNA damage response inhibitors

Z. Szallasi, Deepa T. Patil, Harshabad Singh, 2023, bioRxiv.

Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders

Lestat R. Ali, W. Goessling, J. Meyerhardt, 2024, Journal for ImmunoTherapy of Cancer.

Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting

Harshabad Singh, Z. Sztupinszki, S. Spisák, 2024, NPJ precision oncology.